Shots:

• The first patient has been dosed in a P-II clinical trial evaluating the efficacy and safety of IBI362 (GLP-1R and GCGR dual agonist) in a patient with overweight or obese in China
• The 1EPs of the study are to evaluate the change from baseline in body weight @24 wks.- and to recommend the optimal dose for P-III studies
• The P-I study for IBI362 demonstrates a good safety profile and has the potential for clinically- weight loss- and multiple metabolic benefits. Innovent has entered into a licensing agreement with Eli Lilly for the development and commercialization of OXM3 in China while Lilly is developing OXM3 (Ex- China)

  | Ref: Business Wire | Image:  Innovent